COMMUNIQUÉS West-GlobeNewswire

Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors
21/10/2026
— STRO-006 is Sutro’s second wholly-owned ADC to enter the clinic in less than one year — — Initial clinical data expected in the second half of 2027 — SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- [...]
Arbor Biotechnologies Nominates Three Gene Editing Development Candidates for ALS, with Potential to Address Up to 97% of People Living with the Disease
21/10/2026
Programs span familial and sporadic ALS, advancing Arbor’s strategic focus on the disease First CNS investigational new drug (IND) filings are anticipated in 2027 Milestone builds on clinical development expertise [...]
Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026
21/10/2026
DUBLIN and BRIDGEWATER, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report third [...]
Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
21/10/2026
BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses
21/10/2026
Seven presentations include pediatric Phase 4 studies of AZSTARYS® (Serdexmethylphenidate/dexmethylphenidate) CII and real-world research of JORNAY PM® (Delayed-Release/Extended-Release Methylphenidate) CII in adults [...]
Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026
21/10/2026
FOSTER CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today [...]
Hyro’s new brand identity champions Agentic Care Communications, rallying the healthcare industry around delivering Care OnCue™
21/10/2026
New brand identity centers on agentic adoption at scale, orchestrating staff, systems, and workflows around patient access, IT service management, revenue cycle, and clinical support, so care reaches patients in the [...]
PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026
21/10/2026
Analysis demonstrates a lower bacterial burden in breakthrough surgical-site infections, with similar proportions of multidrug-resistant organisms between treatment groups PETACH TIKVA, Israel, Oct. 21, 2026 (GLOBE [...]
Voyager Announces CEO Succession Plan, Appoints Robin Swartz President
21/10/2026
- Robin Swartz, Voyager’s Chief Business and Operating Officer, appointed President, effective immediately; expected to succeed Alfred W. Sandrock, Jr., M.D., Ph.D., as CEO in Q1 2027 - - Dr. Sandrock expected to remain [...]
VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling
21/10/2026
Patient-derived liver and intestinal disease models are designed to help drug developers test whether a candidate reduces human disease in tissue before it reaches clinical trials SAN DIEGO, Oct. 21, 2026 (GLOBE [...]
Santa Ana Bio to Present Preclinical Data on SAB05, a CD40-Targeted Glucocorticoid Antibody-Drug Conjugate, at ACR Convergence 2026
21/10/2026
ALAMEDA, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Santa Ana Bio, a clinical-stage precision immunology company, today announced that preclinical data on SAB05, its CD40-targeted glucocorticoid antibody-drug conjugate ( [...]
Onicor Appoints Antifungal Pioneer Piet De Doncker, PhD, as CEO to Advance Personalized Treatment for Fungal Nail Infections
21/10/2026
Developer of itraconazole pulse therapy to lead Onicor's personalized nail orthosis for onychomycosis, a common and hard-to-treat condition, into its next phase TILBURG, the Netherlands, 21 October 2026 – Onicor , a [...]
IMUNON Announces Strategic Sale of ThermoDox®
21/10/2026
Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial Sale Reinforces IMUNON's Commitment to Its Core [...]
Pluri Chairman and Active Investor Alejandro Weinstein to Acquire EIB Loan, in Strong Vote of Confidence in the Company
21/10/2026
Chairman-led transaction marks the first step in a broader series of actions to provide a more flexible framework to support the Company's commercial plans HAIFA, Israel, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. ( [...]
10X Health Launches Metabolism Genetic Test
21/10/2026
A saliva-based test provides genetic insights to help inform personalized nutrition and weight-management plans SCOTTSDALE, Ariz., Oct. 21, 2026 (GLOBE NEWSWIRE) -- 10X Health , a leader in personalized health [...]
Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
21/10/2026
Nearly one in three adults who were still smoking or vaping after a prior ORCA trial had quit at the end of a year of cytisinicline treatment, with quit rates rising through the year Among the participants new to [...]
HeartSciences Files Definitive Proxy Statement for Proposed Business Combination with Fortitude Mining
21/10/2026
Shareholder Special Meeting Scheduled for November 19, 2026 Definitive proxy statement filed with the SEC, marking an important milestone toward completion of the proposed transaction HeartSciences Board of Directors [...]
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease
21/10/2026
-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy -- -- Second preclinical study shows inhibitory effects of sotagliflozin on platelet [...]
TaiMed Biologics Reports IDWeek 2026 Data Highlighting TMB-365 and Its Potential Across Long-Acting HIV Combinations
21/10/2026
Phase 1 results demonstrate TMB-365 antiviral activity and tolerability, supporting continued development as a differentiated antibody for combination HIV treatment Complementary laboratory susceptibility findings [...]

Pages